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ABSTRACT  
Rapid development has achieved in treating tumor to stop malignant cell growth and metastasis in the past decade. Numerous researches have 
emerged to increase potency and efficacy with novel methods for drug delivery. The main objective of this literature review was to illustrate the 
impact of current new targeting methods to other previous delivering systems to select the most appropriate method in cancer therapy. This review 
first gave a brief summary of cancer structure and highlighted the main roles of targeting systems. Different types of delivering systems have been 
addressed in this literature review with focusing on the latest carrier derived from malarial protein. The remarkable advantages and main 
limitations of the later have been also discussed. PubMed and Science Direct were the main search engines that have been used as information 
sources to prepare this review. Articles related to cancer targeting system, active and passive processes, current nanoparticles, antibody carriers, 
and current novel cancer carriers were used as sources in this review. Important points from many references published in the last decade (2008-
2018) were selected and included. Several targeting methods were introduced to enhance the efficacy and tolerability of the toxic drug by active and 
passive processes, but there is still no conclusive carrier without certain drawbacks. A combination of targeting methods probably shows the most 
appropriate choice for increasing selectivity and safety of anticancer drugs via reducing the concentration of carriers used.  
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Cancer is the second leading cause of death in developed countries 
after cardiovascular diseases. According to the World Health 
Organization (WHO), over nine million new cases of cancer were 
diagnosed each year with a high mortality rate exceeding 9.6 million 
deaths in 2018 [1]. The past decades have shown a rapid development 
of cancer therapy to stop the growth and metastasis of the tumor. 
However, due to the lower selectivity of anticancer drugs to 
differentiate between malignant and normal cells, serious adverse 
effects appear as a major issue. Therefore, targeting cancer cells has 
emerged as a priority of researchers to develop a safe and selective 
method for delivering the drug directly into the malignant cells [2]. 
Recently, several studies have attempted to create an ideal method for 
drug delivery with higher safety and efficacy. The latest research 
conducted by Salanti et al. has been considered as a unique example of 
these studies and it will be the focus of this literature review with 
other novel targeting methods since it suggests a promising targeting 
system by using selective carriers derived from malarial protein [3].  
Search criteria 
Articles related to cancer targeting system, active and passive 
processes, current nanoparticles, antibody carriers, and current 
novel cancer carriers were used as sources in this review. Authors 
selected and took the important points from many references 
published in 2008-2018. 
Cancer structure 
Cancer is a group of diseases characterized by the spread of abnormal 
cells that have uncontrolled high multiplication rate as a result of 
alteration, up or down-regulation, in gene expression, which is caused 
by genetic, epigenetic, or environmental factors [4-6]. The continuous 
growth of these cells forms a mass in various sizes depending on 
disease level and the affected tissue. This mass can obtain nutrient 
from the body by either a passive method, when the cancer size is less 
than 2 mm3
The past decades have seen rapid development in cancer therapy 
with powerful cytotoxic drugs in order to stop cell proliferation and 
treat this disease. However, because cancer and some normal cells 
share the same internal components, the rest of the body can be 
affected by these drugs resulting in serious side effects that can lead 
to suspending many treatment regimens. These adverse effects 
include bone marrow toxicity, delay in wound healing, hair loss, 
growth retardation in children, teratogenicity, and carcinogenicity as 
a result of the mutagenic effect of drugs [4, 5]. For this reason, it is 
imperative to minimize unwanted effects by creating a new 
delivering system to increase the selectivity and bioavailability of 
anticancer drugs at the site of action. 
 or from abnormal leaky vasculature with pore size ranging 
from 100 to 780 nm which is considered too large compared with 
normal pore 8-10 nm [7]. In addition, cancer cells have other features 
which can be distinguished from normal cells, such as 
dedifferentiation properties combining with loss of usual action, 
penetrability, and metastasis action to affect other tissues [4].  
Role of targeting system 
The past thirty years have seen progressively rapid developments in 
the field of targeted anticancer drugs. The baseline of this field 
depends mainly on two major methods, passive and active process 
[2, 7-11]. The former relates directly to the nature of tumor capillary 
vessels, and the later depends on the interaction mechanism with 
cancer cells. In terms of the passive technique, researchers 
developed a special type of carrier molecules, which have a particle 
size larger than normal pore in the non-cancerous vasculature. 
Consequently, these molecules have a higher tendency to 
accumulate specifically in tumor mass rather than the rest of the 
body as a result of the high leaky vasculature in the tumor site [7]. In 
addition, due to the lack of a clearly defined lymphoid system in 
cancer tissue, carrier molecules tend to reside in the tumor mass for 
a long period of time [8]. The combination of the above reasons can 
explain the delivery system of the passive method and the possibility 
to increase drug selectivity. However, the selectivity degree of this 
method is still, clinically, under expectation and more improvements 
are needed to achieve full activity.  
On the other hand, the active method was introduced to overcome 
some difficulties of the passive technique and optimize the targeting 
level of anticancer drugs. This method was divided into two major 
groups: targeting that depends on the direct interaction between 
carrier and cancer cells and that, which uses physical signals as the 
main part of the system [10, 11]. In the active interaction process, 
carrier molecules have been designed to interact with cancer cells 
directly by either an antigen-antibody reaction or ligand-receptor 
pathway [2, 12]. Folate receptors, for instance, may be highly 
expressed in cancer cells compared with normal tissue due to high 
folate required for tumor growth. By a combination of folic acid with 
targeting molecules in vivo, the efficacy of anticancer drugs can 
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increase into 10 folds with a significant reduction in the systemic 
toxicity [8, 13]. These results encourage researchers to develop 
similar methods and examine different additional enhancements to 
optimize the targeting technique.  
Recently, with the application of cutting-edge technology and 
extended research, the physical signals system has emerged as a 
promising improvement. One example of these systems is by 
developing new particles with a heat sensor that have a tendency to 
be permeable when the temperature exceeds 42 C ° that mainly 
occurs in cancer tissue. After that, the drug can be specifically 
released at that site [14-17]. In some circumstances, using 
hyperthermic agents to elevate the temperature of the targeting 
tissue or applying an external source of heat such as ultrasound or 
electromagnetic power could have extra beneficial effects to ensure 
the process of the drug release [14]. Similar to thermal field design, 
the additional magnetic molecule or use of polymers with magnetic 
properties in the synthesis of carrier molecules is showing 
additional advantages in the targeting process after applying 
external magnetic field [18-20]. However, although these methods 
seem to be the best solution to avoid the unwanted effects of 
anticancer drugs, there are some limitations that need to be 
considered to choose the most appropriate carrier molecule.  
Types of targeting carriers 
• Nanoparticles 
Nanocarriers, the largest group of the targeting system, have been 
introduced to increase the bioavailability, selectivity, and tolerability 
of anticancer drugs. They are characterized by a colloidal structure 
with a particle size ranging from 10 to 1000 nm [7, 17, 21-23]. 
Nanoparticles have been designed to accept drug molecules by 
dissolving, attaching, encapsulating or by the entrapping process 
and delivering them directly to the site of action by the passive 
method [21, 24]. There are several types of these particles 
depending on their method of preparation, such as liposomes, 
micelles, nanospheres, nanocapsules, and dendrimers, as shown in 
fig. 1 [11, 17]. Liposomes represent the most important 
nanoparticles with wide applications in cancer therapy. They are 
composed of two double layers of lipid surrounding an aqueous 
matrix and having a large particle size to ensure accumulation in the 
cancer tissue [23, 25, 26]. This unique composition gives liposomes 
the capability to carry different types of molecules with different 
chemical nature. Once the carrier reaches the site of action, it 
disintegrates and liberates drug molecules as a result of interstitial 
pressure inside the cancer tissue [27, 28]. 
 
 
Fig. 1: Types of nanoparticles [11] 
 
 
Fig. 2: Passive and active targeting methods by using nanoparticles [29] 
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However, liposomes could remain in circulation for a short period 
due to rapid elimination via the reticular endothelial system (RES). 
Moreover, electrostatic and hydrophobic power in the liposomes 
might result in structural collapse [7]. For these reasons, a large 
number of studies have introduced to increase the selectivity of 
nanoparticles by incorporating physical signal active methods 
with the current passive one (fig. 2) [9, 13-15, 17, 18]. In general, 
even though the combination of methods could accumulate 
nanoparticles at the site of action and decrease the side effects of 
anticancer drugs, the therapeutic efficacy still has some concerns. 
This might be due to the lack of assurance of releasing the drug 
from the carriers into the interstitial fluid and reaching the cancer 
cells [15]. That is why it is necessary to expand knowledge and 
researches to develop this method and add extra techniques to 
increase drug efficacy. 
• Antibodies 
Antibody-drug conjugates system (ADCs) has appeared as a promising 
active method in targeting cancer and has been developed to 
overcome some issues of efficacy in nanoparticles [30]. Previously, 
antibodies were discovered and cloned for use in cancer therapy by 
different mechanisms, such as a direct toxic effect [31] or indirect 
stimulation of body immunity [32]. The high specificity of antibodies in 
targeting tumor cells’ antigen and their ability to accept extra 
molecules by conjugation process open new fields toward researchers 
to develop a novel delivering system. The system is composed of three 
important elements: monoclonal antibody (mAb), high potent toxic 
molecules and a stable linker (fig. 3) [30, 32-34]. Interestingly, several 
drug molecules can attach single mAb by numerous linkers which 
increase the possibility to accumulate a high concentration of toxic 
agent at the site of action [35]. 
  
 
Fig. 3: Structure of the ADSs [36] 
 
The main mechanism of ADCs depends on direct interaction and 
complex formation of mAb and particular antigen, a protein produced 
on the surface membrane of cancer. This complex internalizes from 
the membrane into the cells and undergoes degradation by cellular 
lysosomal activity to break down the chemical linker and liberate free 
toxic molecules (fig. 4) [30]. Generally, cancer cells have a tendency to 
express antigen in higher proportion compared with the rare amount 
in normal cells [32, 33]. Therefore, a large number of studies 
conducted to discover specific antibodies for these antigens and 
initiate the reaction for optimum targeting. In the previous decades, 
over 20 antibodies have been discovered and used to develop a 
powerful anticancer drug [37]. Brentuximab Vedotin (Adcetris), 
Trastuzumab-DM1 (Kadcyla), and Gemtuzumab Ozogamicin 
(Mylotarg) are considered as main examples of approved drugs that 
used ADCs technique for treating Hodgkin lymphoma, breast cancer, 
and acute myeloid leukemia, respectively [33, 36, 38]. 
  
 
Fig. 4: The mechanism of ACDs [38] 
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Serious side effects have emerged after using these drugs ranging 
from chills and fever to leukopenia and an increase in the mortality 
rate which resulted in the withdrawal of Mylotarg from the market 
in 2010 [39]. The reason might be due to the ability of antibodies to 
express high antigenicity and toxic effects inside the body when used 
in large doses. Consequently, current researches attempt to increase 
the safety of ACDs by reducing the dose of antibody and using very 
potent suspended toxic molecules to compensate for the efficacy of 
the original drugs [10]. Another considerable issue that has 
appeared is related to the amount of suspending drug molecules for 
each mAb and the type of linker. Nevertheless, increasing attached 
drugs leads to a decrease in the binding ability of mAb with the 
targeted antigen which can lose its activity as a consequence [35]. 
Additionally, an inappropriate type of linker can either prevent 
dissociation of the drug inside cells or cause association failure 
through circulation [38]. Therefore, in order to avoid the above 
problems, it is necessary to choose the suitable binder type and 
determine the amount of drugs carried by the vehicle carefully. 
Further researches are also needed in order to increase the stability 
and safety of ADCs. 
• Malaria carrier protein 
Researchers continue screening for an alternative carrier to avoid 
limitations of current targeting systems. A purified recombinant 
protein called VAR2CSA (rVAR2) represents one example of the 
recent vehicles which might have a role in the future for cancer 
therapy. This protein derived from erythrocyte cells were infected 
by an engineered modified malaria parasite (Plasmodium 
falciparum) [3]. During malaria infection, the parasite tends to 
produce this kind of proteins on the external layer of infected 
erythrocytes as a defense mechanism to avoid elimination by the 
clearance process of the body in the spleen [40]. VAR2 proteins have 
high adhesion properties, which enable the erythrocyte to attach 
intensely into the interstitial tissues by special receptors called 
chondroitin sulfate glycosaminoglycan (CSA). Although these 
receptors expressed in various sites of the human body, studies 
showed that malaria bind specifically to the placenta tissue by 
definite subtype of CS (pl-CSA) [41, 42].  
So far, placental cells have been proposed to have similar 
characteristics of cancer cells due to their higher ability of 
proliferation and invasion of other tissues. Consequently, there are 
many attempts carried out to evaluate the relationship between 
these cells to understand the nature of cancer development and the 
ability of the body to control overproduction of placenta cells [3, 43]. 
The recent study conducted by Salantni et al. showed that cancer 
cells express the same receptor of pl-CS in the plasma membrane or 
in the surrounding stroma of various tumor tissues with a high 
proportion. They examined a large number of different kinds of 
cancer cell lines and found approximately 95% of them interact with 
rVAR2 with variable affinities. Interestingly, this interaction can be 
reversed by the addition of soluble CSA to the cultures due to the 
competition mechanism, which showed that the binding of rVAR2 is 
concentration dependent [3]. These results have encouraged 
researchers to further investigate the ability of rVAR2 in targeting 
cancer cells in vivo and delivering anti-cancer drugs directly at the 
site of action. 
To examine the targeting ability of rVAR2, diphtheria toxin 
associated with rVAR2 (rVAR2-DT) by a diffusion process was used 
as a targeting system to investigate the efficacy of malarial proteins 
in both in vitro and in vivo cancer models. The in vitro studies 
showed a remarkable effect of rVAR2-DT to kill epithelial and 
mesenchymal cancer cells with no effect on normal human cells. 
These studies supported by in vivo researches used mice models 
which revealed that the rVAR2-DT has a high selectivity to deliver 
the toxic drug into various types of tumor tissues, such as prostate 
cancer, with the absence of toxicity effects on the normal tissue [3]. 
However, this selectivity is concentration dependent and a higher 
amount of diphtheria toxin is needed to produce anticancer effects. 
According to the previous clinical trials, the higher concentration of 
this toxin is not well tolerated by the human body [3]. Therefore, 
researchers attempted to reduce the dose of incorporating a toxic 
agent to increase drug tolerability and eliminate side effects. 
To avoid the higher concentration issue, researchers developed a 
new targeting system that incorporates rVAR2 with a potentially 
toxic agent called as KT886, an analog of hemiasterlin toxin, by a 
special protease linker [3]. The KT886 toxin is modified antimitotic 
peptide derived from the marine sponge extract which has a higher 
potency than diphtheria toxin [44]. The rVAR2-KT886 system can 
carry more than one molecule of KT886 without disturbing the 
integrity to produce optimum toxic effects into the site of action with 
lower concentration. This system showed a potent and selective in 
vivo cytotoxicity to different tumor tissues containing pl-CS 
receptors with no detectable side effects. Moreover, the study 
measured the proportion of internalizing molecule into cancer cells 
and demonstrated that the rVAR2-KT886 has a high penetration rate 
and delivering toxic drug internally into cancer cells [3]. Depending 
on these impressive results, it seems that rVAR2 might be a 
prospective alternative method to the other current targeting 
carriers in treating cancer. 
Although the remarkable targeting results of the rVAR2 in the 
previous study, there are some concerns about the safety of this 
system in human. The reason is related to the period of previous 
investigations were conducted for 14 d which seems to be 
insufficient to evaluate the full safety profile in normal tissues. In 
addition, the investigation of immunogenic and resistant effects is 
particularly unsuitable to validate with this short period study, 
which needs more time to progress. According to the European 
Medicines Agency (EMA), anticancer drugs need more than three 
months period of nonclinical study for toxicological evaluation prior 
to developing any clinical trials [45]. Therefore, extended in vivo 
studies are required to provide a valid picture for ensuring the use 
of these proteins safely in human patients.  
Besides the safety concern, the efficacy profile of the rVAR2-KT886 
system seems to be another aspect that needs to be considered. As 
with the ADCs, the stability of linkers that used in the rVAR2 
technique might disturb and undergo dissociation process after 
direct exposure to the human blood circulation. Hence, evaluating 
the type of linkers and balancing the amount of suspending toxic 
drugs are essential to avoid any limitation which might result in the 
targeting system collapse.  
Another issue with the Salanti et al. study was related to the fact that 
the researchers used only mice as a model without considering the 
other in vivo models [3]. For instance, rats and rabbits are needed to 
exclude any genetic factors. The particular genetic difference 
between mice and humans might be responsible for variation in the 
immunity system, stress response, and metabolic process [46]. 
Therefore, further researches in different models are required to 
examine the safety and efficacy of rVAR2 system prior to 
establishing any clinical trials in the future. 
 
 
Fig. 5: A combination of nanoparticle with antibodies and other 
active ligands [47] 
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• New approach: combination system 
Despite the particular drawbacks for previous carriers, researchers 
have examined methods to combine different targeting systems for 
synergistic benefits. Depending on the current carriers and with 
accumulative knowledge, many encouraging studies have been 
developed to afford new opportunity to improve the safety and 
selectivity of vehicles. For instance, the combination of nanoparticles 
with antibodies introduces maximum advantages with higher safety 
and selectivity than each carrier alone (fig. 5) [47-50]. This 
combination depends on the capability of nanoparticles to carry a 
large number of toxic drugs and the ability of antibodies to provide 
these drugs specifically into the site of action through the 
endocytosis mechanism [47]. Consequently, the side effects of 
carriers will decrease as a result of a reduction in the concentration 
of vehicles required for delivery. New prospect studies can be 
emerged from this finding to investigate other alternatives and 
compare the activity to choose the most appropriate combination. 
Accordingly, the rVAR2 proteins that showed a higher selectivity in 
the initial in vivo studies seem to be a suitable alternative to examine 
their activity with nanoparticles or other carriers in the prospective 
clinical trials to create a useful vehicle with minimum side effects.  
CONCLUSION 
In the last three decades, significant developments have been 
achieved with the targeting cancer approaches. Different carriers 
using various mechanisms, active and passive methods, have 
appeared as promising vehicles to increase the efficacy of anticancer 
drugs and reduce their unwanted effects. The recent vehicle derived 
from the malaria protein, rVAR2, represents the main example of 
these carriers that showed a high selectivity in cancer in vivo studies 
and a significant reduction in the adverse effects of the suspending 
toxic drugs. The aim of this literature was to evaluate the impact of 
new carriers compared to the other systems and select the best one 
to be used in cancer therapy. Although the diversity of targeting 
methods could enhance the efficacy and tolerability of the toxic drug, 
there is no definitive carrier without certain drawbacks. Depending 
on the current evidence, the combination method of different 
vehicles in one system might be the most appropriate choice to 
increase the selectivity and safety of anticancer drugs by reducing 
the concentration of carriers used. However, substantial researches 
are still needed to be dedicated to the targeting field in order to 
exploit the safest and most applicable vehicle option. 
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